-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades Catalyst Pharmaceuticals to Neutral, Lowers Price Target to $31.5

Benzinga·05/28/2026 16:43:06
Listen to the news
HC Wainwright & Co. analyst Andrew S. Fein downgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) from Buy to Neutral and lowers the price target from $35 to $31.5.